title: [Clinical effects and safety of piperacillin/tazobactam in treating neutropenic febrile patients with malignant hematopathy].
abstract: OBJECTIVE
  To evaluate the effect and safety of piperacillin/tazobactam on neutropenic febrile patients with Malignant Hematopathy.
  
  
  METHODS
  218 patients with malignant hematopathy complicated by infectious fever, 162 (74.31%) with fever of unknown origin (FUO), 33 (15.14%) with clinically defined infection (CDI), and 23 (10.55%) with microbiologically defined infection (MDI), underwent intravenous drip of piperacillin/tazobactam at the dose of 4.5 g for 30 min every 8 hours till 4 - 5 d after the temperature returned to normal or neutropenia was relieved. Twenty hours before and after treatment blood routine, blood biochemical and electrolytes, and bacteriological examination, chest X-ray examination were conducted. The changes of symptoms and signs were observed.
  
  
  RESULTS
  The total effective rate was 65.60%, the bacteria clearance rate was 71.43%, and the adverse reaction rate was 5.04%. The average defervescence time was (2.5 +/- 1.2) days, and the duration of antibiotic therapy was (9.4 +/- 8.1) days. There were not significant differences in the curative effect and defervescence time between the patients undergoing chemotherapy and those undergoing hematopoietic stem cell transplantation (chi2 = 2.058, P > 0.05, and t = 1.892, P > 0.05). After the piperacillin/tazobactam treatment the white blood cell count and absolute neutrophile granulocyte count of the patients significantly increased (t = 4.092, P < 0.01; t = 4.248, P < 0.01). However, the hepatic and renal functions did not change obviously after treatment.
  
  
  CONCLUSIONS
  Piperacillin/tazobactam therapy is effective and safe empirical antibacterial therapy in febrile neutropenic patients with hematological malignancies.
authors.affiliation: Institute of Hematology, People's Hospital of Beijing University, Beijing 100044, China.
authors.forename: Kai-Yan
authors.initials: KY
authors.lastname: Lu
authors.forename: Jin-Song
authors.initials: JS
authors.lastname: Jia
authors.forename: Juan
authors.initials: J
authors.lastname: Li
authors.forename: Chun
authors.initials: C
authors.lastname: Wang
authors.forename: De-Pei
authors.initials: DP
authors.lastname: Wu
authors.forename: Liang-Ding
authors.initials: LD
authors.lastname: Hu
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Huang
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000188:drug therapy*; D010397:Penicillanic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010878:Piperacillin / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D000078142:Tazobactam; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D010397:Penicillanic Acid; D000078142:Tazobactam; D010878:Piperacillin